Assessment of the use of sialogogues in the clinical management of patients with xerostomia

Special Care in Dentistry

Volumn 26, Issue 4, 2006, Pages 164-170

  Chainani Wu, Nita ^a   Gorsky, Meir ^b   Mayer, Priscilla ^a   Bostrom, Alan ^c   Epstein, Joel B ^d,e   Silverman Jr , Sol ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Bethanechol; Cevimeline; Dry mouth; Pilocarpine; Sialogogue; Xerostomia

Indexed keywords

BETHANECHOL; CEVIMELINE; MUSCARINIC AGENT; PILOCARPINE; QUINUCLIDINE DERIVATIVE; THIOPHENE DERIVATIVE;

ARTICLE; BACTERIAL COUNT; CANDIDA; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; SALIVA; SALIVATION; SPEECH; SWALLOWING; SWEATING; TASTE; THRUSH; XEROSTOMIA;

BETHANECHOL; CANDIDA; CANDIDIASIS, ORAL; COLONY COUNT, MICROBIAL; CROSS-OVER STUDIES; DEGLUTITION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MUSCARINIC AGONISTS; PILOCARPINE; QUINUCLIDINES; SALIVA; SALIVATION; SPEECH; SWEATING; TASTE; THIOPHENES; XEROSTOMIA;

EID: 33749163835     PISSN: 02751879     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1754-4505.2006.tb01719.x     Document Type: Article

References (24)

1. Cassolato SF, Turnbull RS. Xerostomia: clinical aspects and treatment. Gerodontology 2003;20:64-77.
2. Pajukoski H, Meurman JH, Halonen P, Sulkava R. Prevalence of subjective dry mouth and burning mouth in hospitalized elderly patients and outpatients in relation to saliva, medication, and systemic diseases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;92:641-9.
3. Schuller DE, Stevens P, Clausen KP, Olsen J, Gahbauer R, Martin M. Treatment of radiation side effects with oral pilocarpine. J Surg Oncol 1989;42:272-6.
4. Gorsky M, Epstein JB, Parry J, Epstein MS, Le ND, Silverman S Jr. The efficacy of pilocarpine and bethanechol upon saliva production in cancer patients with hyposalivation following radiation therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;97:190-5.
5. Epstein JB, Burchell JL, Emerton S, Le ND, Silverman S Jr. A clinical trial of bethanechol in patients with xerostomia after radiation therapy. A pilot study. Oral Surg Oral Med Oral Pathol 1994;77:610-4.
6. Fife RS, Chase WF, Dore RK et al. Cevimeline for the treatment of xerostomia in patients with Sjogren syndrome: a randomized trial. Arch Intern Med. 2002;162:1293-300.
7. Greenspan D, Daniels TE. Effectiveness of pilocarpine in postradiation xerostomia. Cancer 1987;59:1123-5.
8. Fox PC, Atkinson JC, Macynski AA et al. Pilocarpine treatment of salivary gland hypofunction and dry mouth (xerostomia). Arch Intern Med 1991;151:1149-52.
9. Johnson JT, Ferretti GA, Nethery WJ et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med 1993;329:390-5.
10. Sangthawan D, Watthanaarpornchai S, Phungrassami T. Randomized double blind, placebo-controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. J Med Assoc Thai 2001;84:195-203.
11. Lajtman Z, Krajina Z, Krpan D, Vincelj J, Borcic V Popovic-Kovacic J. Pilocarpine in the prevention of postirradiation xerostomia. Acta Med Croatica 2000; 54:65-7.
12. Horiot JC, Lipinski F, Schraub S et al. Postradiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study. Radiother Oncol 2000;55:233-9.
13. Niedermeier W, Matthaeus C, Meyer C, Staar S, Muller RP, Schulze HJ. Radiation-induced hyposalivation and its treatment with oral pilocarpine. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 86:541-9.
14. Everett HC. The use of bethanechol chloride with tricyclic antidepressants. Am J Psychiatry 1975;132:1202-4.
15. Silverman S Jr. Oral cancer. 3rd ed. Atlanta, Ga.: American Cancer Society 1990:82.
16. Iwabuchi Y, Masuhara T. Sialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: identification of a potential therapeutic agent for treatment of Sjögren's syndrome. Gen Pharmacol 1994;25:123-9
17. Petrone D, Condemi JJ, Fife R, Gluck O, Cohen S, Dalgin P. A double-blind, randomized, placebo-controlled study of cevimeline in Sjogren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum 2002;46:748-54.
18. Iga Y, Arisawa H, Ogane N et al. (+/-)-cis-2-methylspiro[1,3-oxathiolane- 5,3′-quinuclidi ne] hydrochloride, hemihydrate (SNI-2011, cevimeline hydrochloride) induces saliva and tear secretions in rats and mice: the role of muscarinic acetylcholine receptors. Jpn J Pharmacol 1998;78:373-80.
19. Washio T, Kohsaka K, Arisawa H, Masunaga H. Pharmacokinetics and metabolism of the novel muscarinic receptor agonist SNI-2011 in rats and dogs. Arzneimittelforschung 2003;53:26-33.
20. Omori Y, Asari T, Maruyama K, Kusama H, Kojima M, Shibata N. Effects of pilocarpine hydrochloride and cevimeline on submandibular/sublingual salivation in rat xerostomia model produced by X-ray irradiation. Arzneimittelforschung 2003;53:342-50.
21. Washio T, Kohsaka K, Arisawa H, Masunaga H, Nagatsuka S, Satoh Y. Pharmacokinetics and metabolism of radiolabelled SNI-2011, a novel muscarinic receptor agonist, in healthy volunteers. Comprehensive understanding of absorption, metabolism and excretion using radiolabelled SNI-2011. Arzneimittelforschung 2003;53:80-6.
22. 2004 Physicians' Desk Reference: Urecholine. Thomson PDR, 2004:2095.
23. 2004 Physicians' Desk Reference: Salagen. Thomson PDR, 2004:2130.
24. 2004 Physicians' Desk Reference: Evoxac. Thomson PDR, 2004:1182.